DELSTRIGO是固定剂量的组合产品,其中包含100毫克Doravirine(DOR),300毫克拉米夫定(3TC)和300毫克TDF。成人DELSTRIGO的推荐剂量是每天口服一次,含或不含食物 肾功能不全 由于DELSTRIGO是固定剂量的组合片剂,并且拉米夫定和TDF的剂量无法调整,因此对于肌酐清除率估计低于50 mL / min的患者,不建议使用DELSTRIGO 利福布汀的剂...
You should not use Delstrigo if you are allergic to doravirine, lamivudine, or tenofovir. Many drugs can interact and cause dangerous effects. Some drugs should not be used together with Delstrigo. Your doctor may change your treatment plan if you have used any of the following medicines in ...
•Delstrigo每天服用1次,每天大约在同一时间。 •Delstrigo通常自行服用(不含其他HIV-1药物)。 •如果您在Delstrigo治疗期间服用利福布丁,您的医生也会为您开出额外剂量的多拉韦林。仔细按照医生的指示服用何时服用多拉韦林以及服用多少剂量。通常在最后一剂该药•可与食物一起服用或在两餐之间服用。 •不要在...
Delstrigo is a medication used to treat HIV. It is a combination of three separate antiretroviral drugs in one pill, taken once a day. It combines 100mg of doravirine, 300mg of lamivudine and 245mg of tenofovir disoproxil fumarate in a yellow tablet with ‘776’ on one side of the tabl...
2. Delstrigo Dosage and Administration 2.1 Testing When Initiating and During Treatment with DELSTRIGO Prior to or when initiating DELSTRIGO, test patients for HBV infection [see Warnings and Precautions (5.2)]. Prior to or when initiating DELSTRIGO, and during treatment with DELSTRIGO, on a ...
2020年12月31日,中国国家药监局(NMPA)官网公示默沙东(MSD)公司开发的Delstrigo(DOR/3TC/TDF)多拉韦林/拉米夫定/替诺福韦片 上市治疗HIV-1感染且无NNRTI(非核苷逆转录酶抑制剂)类药物拉米夫定或替诺福韦耐药性的既往或现有证据的成年患者。 图片:Delstrigo(德思卓) ...
HIV新药!默沙东Delstrigo和Pifeltro获欧盟批准美国制药巨头默沙东(Merck & Co)近日宣布,欧盟委员会(EC)已批准Delstrigo和Pifeltro,用于治疗HIV-1感染。该公司已计划在2019年上半年将这2个药物推向欧洲市场。Delstrigo是一种三合一复方药物,由固定剂量的新型非核苷类逆转录酶抑制剂(NNRTI)doravirine(DOR,100mg)与拉米夫定...
作用机制:DELSTRIGO是抗逆转录病毒药物多拉韦林,拉米夫定和TDF的固定剂量组合[见微生物学]。适应症和用法:DELSTRIGO是多拉韦林(一种非核苷逆转录酶抑制剂[NNRTI]),拉米夫定和富马酸依诺福乐富马酸盐(均为核苷类似物逆转录酶抑制剂)的三药联合用药,可作为治疗成人非抗逆转录病毒患者HIV-1感染的完整方案。剂量和给药...
2018年8月30日,默沙东艾滋病STR(Single-Tablet Regimens)药物Delstrigo(doravirine 100 mg/ TDF 300 mg/ 3TC 300 mg )获批上市,这又是一款2NRTI/NNRTI药物。但是,药物市场预期并不看好,Delstrigo是一款TDF基本组成的2NRTI/NNRTI,药物无法重现Atripla(efavirenz+ TDF + FTC)的销售辉煌,也无法扭转Atripla的颓势。
Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor [NNRTI]), and two nucleoside analogue reverse transcriptase inhibitors indicated as a complete regimen for the treatment of HIV-1 infection in adult pati...